Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

LLYSNY

Eli Lilly and Company

Area by area

Overall Quant Score

How does it look overall? (out of 100)

LLY

70/100

SNY

60/100

Quality

Is it a profitable, well-run business?

LLY

9.4/10

SNY

3.9/10

Growth

Is the company growing?

LLY

10.0/10

SNY

4.6/10

Valuation

Is the price reasonable? (higher = cheaper)

LLY

3.4/10

SNY

9.4/10

Risk

How risky are the shares? (higher = lower risk)

LLY

7.4/10

SNY

7.9/10

Momentum

Is the share price trending up?

LLY

9.5/10

SNY

6.3/10

Financial strength

Is the balance sheet healthy?

LLY

7.1/10

SNY

4.9/10

The balanced view

Model-generated

Eli Lilly and Company

This company scores above average, with solid growth and a positive price trend, although its current valuation deserves attention.

Leads on: quality, growth, momentum, financial strength

Best feature: solid growth (Revenue growth (FY): 44.7%)

Watch out: valuation may be demanding (DCF upside: -43.2%)

Sanofi

This company scores above average, with a reasonable valuation and a relatively low-risk profile, although its profitability is thin.

Leads on: valuation, risk

Best feature: reasonable valuation (Price / FCF: 5.4x)

Watch out: profitability is thin (Return on equity (TTM): 5.5%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.